Clinical trial
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
NCT02886065 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 7, 2017
- Completion date
- February 15, 2027
- Enrollment
- 19 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.